$AWHL · Aspira Women's Health Inc.
Aspira Women's Health filed an 8-K under Item 4.02 disclosing that its Audit Committee concluded the unaudited condensed consolidated financial statements for the three and six months ended March 31 and June 30, 2026 should no longer be relied upon. The errors relate to misclassification of a January 2026 Agile loan and related payments, which were reported in operating activities instead of financing activities under ASC Topic 230. The restatement had no impact on balance sheets, statements of operations, or total net change in cash. Management concluded the matter resulted in a material weakness in internal control over financial reporting, with disclosure controls and procedures deemed ineffective for the affected periods.
- Audit Committee concluded Q1 and Q2 2026 cash flow statements should no longer be relied upon.
- January 2026 Agile Loan proceeds of $1,050K were misclassified as operating instead of financing activities.
- Restatement had no impact on balance sheets, statements of operations, or total net change in cash.
- Management identified a material weakness in internal control over financial reporting.
- Disclosure controls and procedures were deemed ineffective for the affected periods.
Price data unavailable.
A non-reliance determination and material weakness disclosure signal control failures that can precede further restatements or regulatory scrutiny.
_Not applicable._
Material weakness in internal control over financial reporting; disclosure controls and procedures ineffective for the affected periods. Remediation requires controls to operate for a sufficient time and pass testing.